Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 3/20 | 0.70 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.66 |
| ▸ | CTNNB1 | P35222 | 3/20 | 0.64 |
| ▸ | TCF4 | P15884 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.64 |
| ▸ | FABP4 | P15090 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 5/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.61 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.60 |
| ▸ | CISD1 | Q9NZ45 | 2/20 | 0.59 |
| ▸ | MAOA | P21397 | 1/20 | 0.59 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.59 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.58 |
| ▸ | DDX3X | O00571 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12008449 | 0.94 | TAS2R14 (0.76) | TAS2R14KLKB1CTNNB1TCF4ALDH1A1 | |
| SCHEMBL7251139 | 0.90 | TAS2R14 (0.70) | TAS2R14KLKB1CTNNB1TCF4ALDH1A1 | |
| SCHEMBL7251137 | 0.90 | TAS2R14 (0.70) | TAS2R14KLKB1CTNNB1TCF4ALDH1A1 | |
| SCHEMBL12008531 | 0.90 | TAS2R14 (0.70) | TAS2R14KLKB1CTNNB1TCF4ALDH1A1 | |
| SCHEMBL17779690 | 0.90 | AKR1B1 (0.63) | ALDH1A1MAPTMEN1KMT2APSMD14 | |
| SCHEMBL20837934 | 0.90 | AKR1B1 (0.63) | ALDH1A1MAPTMEN1KMT2APSMD14 | |
| SCHEMBL12008741 | 0.89 | KLKB1 (0.77) | TAS2R14KLKB1CTNNB1TCF4ALDH1A1 | |
| SCHEMBL12008747 | 0.88 | TAS2R14 (0.78) | TAS2R14KLKB1CTNNB1TCF4ALDH1A1 | |
| SCHEMBL12008469 | 0.88 | CTNNB1 (0.79) | TAS2R14KLKB1CTNNB1TCF4ALDH1A1 | |
| SCHEMBL12008560 | 0.88 | TAS2R14 (0.64) | TAS2R14KLKB1CTNNB1TCF4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11584727-B2 | 2-thioxothiazolidin-4-one derivatives active as transthyretin ligands and uses thereof | BSIM THERAPEUTICS, S.A. (PT) | 2023-02-21 | — | — | US | disclosed |
| US-11584727-B2 | 2-thioxothiazolidin-4-one derivatives active as transthyretin ligands and uses thereof | BSIM THERAPEUTICS, S.A. (PT) | 2023-02-21 | — | — | US | disclosed |
| US-20220267286-A2 | 2-THIOXOTHIAZOLIDIN-4-ONE DERIVATIVES ACTIVE AS TRANSTHYRETIN LIGANDS AND USES THEREOF | BSIM THERAPEUTICS, S.A. (PT) | 2022-08-25 | — | — | US | disclosed |
| EP-4029859-A1 | 2-OXOTHIAZOLIDIN-4-ONE DERIVATIVES ACTIVE AS TRANSTHYRETIN LIGANDS AND USES THEREOF | BSIM THERAPEUTICS, S.A. (PT) | 2022-07-20 | — | — | EP | disclosed |
| US-20220041566-A1 | 2-THIOXOTHIAZOLIDIN-4-ONE DERIVATIVES ACTIVE AS TRANSTHYRETIN LIGANDS AND USES THEREOF | BSIM THERAPEUTICS, S.A. (PT) | 2022-02-10 | — | — | US | disclosed |
| US-11117877-B2 | 2-thioxothiazolidin-4-one derivatives active as transthyretin ligands and uses thereof | BSIM THERAPEUTICS, S.A. (PT) | 2021-09-14 | — | — | US | disclosed |
| US-11117877-B2 | 2-thioxothiazolidin-4-one derivatives active as transthyretin ligands and uses thereof | BSIM THERAPEUTICS, S.A. (PT) | 2021-09-14 | — | — | US | disclosed |
| US-20190092737-A1 | 2-THIOXOTHIAZOLIDIN-4-ONE DERIVATIVES ACTIVE AS TRANSTHYRETIN LIGANDS AND USES THEREOF | BSIM2 - Biomolecular Simulations Lda. (PT) | 2019-03-28 | — | — | US | disclosed |
| US-20190092737-A1 | 2-THIOXOTHIAZOLIDIN-4-ONE DERIVATIVES ACTIVE AS TRANSTHYRETIN LIGANDS AND USES THEREOF | BSIM2 - Biomolecular Simulations Lda. (PT) | 2019-03-28 | — | — | US | disclosed |
| EP-3221299-A1 | 2-THIOXOTHIAZOLIDIN-4-ONE DERIVATIVES ACTIVE AS TRANSTHYRETIN LIGANDS AND USES THEREOF | BSIM2 Biomolecular Simulations Lda. (PT) | 2017-09-27 | — | — | EP | disclosed |
| WO-2016080853-A1 | 2-THIOXOTHIAZOLIDIN-4-ONE DERIVATIVES ACTIVE AS TRANSTHYRETIN LIGANDS AND USES THEREOF | BSIM2 – BIOMOLECULAR SIMULATIONS LDA (PT) | 2016-05-26 | — | — | WO | disclosed |
| WO-2016080853-A1 | 2-THIOXOTHIAZOLIDIN-4-ONE DERIVATIVES ACTIVE AS TRANSTHYRETIN LIGANDS AND USES THEREOF | BSIM2 – BIOMOLECULAR SIMULATIONS LDA (PT) | 2016-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11117877-B2 | 2-thioxothiazolidin-4-one derivatives active as transthyretin ligands and uses thereof | TTR, TTPA, MTPN | TAS2R14 905/4885KLKB1 3911/4885CTNNB1 1638/4885 |
| US-20220267286-A2 | 2-THIOXOTHIAZOLIDIN-4-ONE DERIVATIVES ACTIVE AS TRANSTHYRETIN LIGANDS AND USES THEREOF | TTR, TTPA, MTPN | TAS2R14 1025/4885KLKB1 3832/4885CTNNB1 1696/4885 |
| US-20190092737-A1 | 2-THIOXOTHIAZOLIDIN-4-ONE DERIVATIVES ACTIVE AS TRANSTHYRETIN LIGANDS AND USES THEREOF | TTR, TTPA, MTPN | TAS2R14 905/4885KLKB1 3911/4885CTNNB1 1638/4885 |
| US-11584727-B2 | 2-thioxothiazolidin-4-one derivatives active as transthyretin ligands and uses thereof | TTR, TTPA, MTPN | TAS2R14 1025/4885KLKB1 3832/4885CTNNB1 1696/4885 |
| US-20220041566-A1 | 2-THIOXOTHIAZOLIDIN-4-ONE DERIVATIVES ACTIVE AS TRANSTHYRETIN LIGANDS AND USES THEREOF | TTR, TTPA, MTPN | TAS2R14 1025/4885KLKB1 3832/4885CTNNB1 1696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.